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Abstract
While numerous cell signaling pathways are known to play decisive roles in chemotherapeutic response, relatively
little is known about the impact of the Smad-dependent transforming growth factor β pathway on the therapeutic
outcome. Previous reports suggested that patients with lung cancer who continue to smoke while receiving chemo-
therapy have a poorer outcome than their nonsmoking counterparts do. In our previous study, we showed that long-
term cigarette smoke condensate (CSC)–mediated down-regulation of Smad3 induces tumorigenesis. The objective
of this study was to determine the mechanism of function of Smad3 in chemoresistance induced by CSC in human
lung cell lines, namely, A549 and HPL1A. Long-term CSC treatment increases the half-maximal inhibitory concen-
tration (IC50) of carboplatin and makes cells resistant to carboplatin. The increase in IC50 of long-term CSC-treated
cells is due to the reduced induction in apoptosis by carboplatin. The increase in IC50 and decrease in apoptosis in
long-term CSC-treated cells is correlated with the expression of Bcl2. We have determined that Bcl2 is both necessary
and sufficient to make the cells resistant to carboplatin. We have also shown that Smad3 acts upstream to regulate
the expression of Bcl2 specifically and, thus, sensitivity of the cells to carboplatin. This is supported by the inverse
correlation between the expressions of Smad3 and Bcl2 in human lung tumors. Collectively, these data suggest that
loss of Smad3 expression in CSC-treated cells induces resistance to carboplatin by upregulating the expression of
Bcl2. This study explains, at least in part, the higher chemoresistance rate observed in smokers.
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Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide [1].
Cigarette smoking is a major risk factor in the development of non–
small cell lung cancer (NSCLC), which accounts for 80% of all lung
cancers [2,3]. Current standard therapies include surgical resection,
platinum-based doublet chemotherapy, and radiation therapy alone or
in combination. Unfortunately, these therapies rarely cure the disease,
and the overall 5-year survival rate is still only 15% [1]. NSCLC is
characterized by its poor prognosis and by resistance to the apoptotic
activity of antineoplastic drugs both in vivo and in vitro [4,5].
Cisplatin, carboplatin, and oxaliplatin are platinum-based drugs that
are widely used in cancer chemotherapy. These agents are commonly
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administered in various tumor types including ovarian, cervical, head
and neck, and NSCLC [6]. Although many cellular components inter-
act with cisplatin, DNA is the primary biologic target of the drug [7].
The cellular outcome of DNA adduct formation is generally apoptotic
cell death. Apoptosis is thought to occur through halting of cellular
processes such as replication and transcription, leading to prolonged
G2-phase cell cycle arrest and deregulation of signal transduction path-
ways involved in normal homeostasis of the cell [8,9]. Many factors
contribute to the cellular mechanisms of resistance to platinum-based
chemotherapeutics and contribute to a severe limitation in their use in
clinical practice. One important mechanism acting downstream of the
initial reaction of cisplatin with DNA is an increase in adduct repair
and a decrease in the induction in apoptosis [9]. Among the significant
cellular pathways that have been demonstrated to play key roles in
platin-induced apoptosis/cytotoxicity, the mitogen-activated protein
kinase cascades, and the tumor suppressor p53 are important [10,11].
Deciphering the mechanisms involved in chemoresistance is critical to
improve our understanding of these complex pathways and to develop
more effective targeted treatments.
Tumor cells often resist to chemotherapy by engaging protective
mechanisms and survival signaling, which can antagonize the chemo-
therapy [12]. Furthermore, apoptosis inhibition is necessary to provide
cancer cells with the ability to survive in a stressful environment; it has
been proposed that oncogenes provide cancer cells with intrinsic resis-
tance. Chemoresistance in several types of cancer has been linked to
the up-regulation of Bcl2 [13]. Overexpression of Bcl2 is associated
with cisplatin resistance, and this is likely facilitated by an increase in
GSH levels [14,15]. However, there are paradoxical findings, which
indicate that Bcl2 overexpression is associated with either improved
survival of ovarian cancer patients receiving cisplatin [16] or increased
sensitivity of tumor cells to cisplatin [17]. So far, however, it has not
been investigated whether overexpression of Bcl2 that is observed in
smokers with NSCLC is only an epiphenomenon or whether it is
mechanistically involved in the development of drug resistance.
Cigarette smoking has been found to induce a number of genetic
and molecular changes in the respiratory tract, including cellular
atypia, loss of heterozygosity [18], and promoter hyper methylation
[19]. Microarray studies of bronchial epithelial cells have indicated
that cigarette smoke induces, primarily, the expression of xenobiotic-
metabolizing and redox-regulating genes but also points to the effects
on tumor suppressor genes, oncogenes, and genes involved in the reg-
ulation of inflammation [20]. Systematic analysis of messenger RNA
(mRNA) and protein expression levels among thousands of genes has
also contributed to defining the molecular network of lung carcino-
genesis. Despite the fact that enormous progress in understanding
the molecular mechanisms leading to lung cancer has been made, very
little attention has been paid to how these molecular changes affect
chemotherapy in smokers.
Recent reports show that nicotine inhibits apoptosis in various cells
lines, which may suggest that nicotine has the ability to reduce the
efficacy of chemotherapeutic agents by stimulating survival pathways
[21–23]. In addition to nicotine, a burning cigarette generates as many
as 6000 other compounds, 60 of them are known to be carcinogens.
Although the toxicity of individual components can be assessed, it is
likely that the biologic response to complex mixtures such as cigarette
smoke is not the sum of multiple independent toxicities. The best
methodology to mimic effect of smoking in humans in vitro would
be to treat human lung cell lines with CSC and examine how that
affects chemotherapy in patients with lung cancer.
The transforming growth factor β (TGF-β) pathway has important
roles in cellular proliferation, angiogenesis, differentiation, migration,
and apoptosis [24]. The TGF-β pathway signals either through the
Smad-dependent pathway or through the Smad-independent pathway
such as extracellular signal–regulated kinase, c-jun N-terminal kinase,
PI3K/AKT, and Rho-like guanosine triphosphatases. Previous studies
have shown that chromosome 18q loss and presence of TGFβRII
mutations correlates with low survival rates in patients with colorectal
cancer treated with adjuvant chemotherapy [25]. Other studies also
showed a direct correlation between low levels of Smad4 in tumors
and worse outcome after surgery and treatment with 5′-fluorouracil
in patients with colon cancer [26]. However, there have not been
any studies elucidating the effect of the expression of Smad3 on the
resistance to chemotherapy observed in patients with lung cancer.
In our recent publication, we found that the Smad3 pathway is
down-regulated in long-term CSC-treated cells, and it contributes
to lung tumorigenesis [27]. Here, we describe the results of a study
in which immortalized human bronchial epithelial cells, HPL1A and
lung adenocarcinoma cell line A549, were chronically exposed to low
doses of cigarette smoke condensate (CSC) for approximately 1 year.
Therefore, we intended to mimic, in vitro, the long-term exposure
of human lung epithelium to smoking. We used this in vitro model
system to evaluate the role of long-term smoking-mediated Smad3
down-regulation in inducing resistance to chemotherapy in patients
with lung cancer. We report here for the first time that reduced
expression of Smad3 by smoking is imparting resistance to carboplatin
in NSCLC by regulating Bcl2.
Materials and Methods
Cell Lines and Cell Culture
Human lung adenocarcinoma cells (A549) obtained from ATCC
(Manassas, VA) and human lung immortalized epithelial cells (HPL1A)
(a kind gift from Dr T. Takahashi),Mycoplasma negative by a polymer-
ase chain reaction detection method (April 10 and October 8, 2010,
testing; Sigma Venor-Gem, St Louis, MO), were maintained in RPMI
with 10% fetal bovine serum (FBS) supplemented with penicillin/
streptomycin and L-glutamate. All cell lines were cultured and main-
tained at 37°C in a humidified incubator in the presence of 5% CO2.
Cells were treated with CSC at 25 μg/ml or with the same volume of
dimethyl sulfoxide (DMSO) as controls for 4100 and 300 days.
MTT Assay
In a 96-well flat-bottomed plate, 2000 cells per 100 μl of cell
suspension were used to seed each well. The cells were incubated over-
night to allow for cell attachment and recovery. Cells were treated with
indicated drugs and incubated for 72 hours at 37°C. After treatment,
10 μl of a 5-mg/ml solution in PBS of the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) tetrazolium substrate
(Millipore, Billerica, MA) was added to each well and incubated for
4 hours at 37°C. The resulting violet formazan precipitate was solubi-
lized by the addition of 100 μl of a 0.04 M HCl in isopropanol solu-
tion. The plates were then analyzed on a microplate reader (MRX;
Dynex Technologies, West Sussex, United Kingdom) at 570 and
630 nm (background) to determine the absorbance of the samples.
Annexin V–PI Staining
Cells were plated at 1 × 106 per 10-cm dish and allowed to grow
overnight and were subsequently treated with carboplatin for 48 hours.
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Single-cell suspensions were labeled with 5 μl of propidium iodide (PI)
and 5 μl of Annexin V (BD Pharmingen, San Jose, CA) and approxi-
mately 105 cells in 1 ml were analyzed by flow cytometry. Ten thousand
cells were evaluated, and the percentage of cells with Annexin V–positive
and PI-negative was determined using the software.
Cell Cycle Analysis
Cells were plated at 1 × 106 per 10-cm dish and allowed to grow over-
night and subsequently treated with carboplatin (70 μM) for 48 hours.
Single-cell suspensions were labeled with 50 μg/ml PI (Sigma, St Louis,
MO), and approximately 106 cells in 1 ml were analyzed by flow
cytometry. Ten thousand cells were evaluated, and the percentage of
cells in the G2 phase was denoted by the 2N population phase, which
was determined using FlowJo Software (Treestar, Inc, Ashland, OR).
Immunoblot Analysis
To measure poly(ADP-ribose) polymerase (PARP) cleavage and
caspase 3 cleavage, 100,000 cells were plated in a 12-well plate
and treated with drug(s) for the indicated times. Detached cells were
collected, and the adherent cells were collected by trypsinization.
Both populations of cells were recombined and washed with PBS
and the cells were lysed. Protein concentrations were estimated with
a bicinchoninic acid assay (Sigma). Proteins were separated on an
8% and 12% SDS-PAGE gel and transferred to nitrocellulose. Levels
of cleaved caspase 3 and cleaved PARP were detected by blot analy-
sis with a polyclonal antibody (Cell Signaling Technology, Danvers,
MA). For detection of Bcl2 family members, a prosurvival Bcl2
family sampler kit was used (Cell Signaling Technology) according to
the manufacturer’s instructions.
Bcl2 and Smad3 Small Interfering RNA Knockdown
For the Bcl2 and Smad3 small interfering RNA (siRNA) knock-
down, 20 nM each of Bcl2 and Smad3 siRNA (Sigma Aldrich) were
transiently transfected into 300-day CSC-treated A549 and HPL1A
(for Bcl2) and A549 and HPL1A Bcl2-overexpressing clones (for
Smad3) using N-ter, a transfection reagent (Sigma Aldrich), according
to the manufacturer’s instructions. A control siRNA (nonhomologous
to any known gene sequence) and transfection just with the transfec-
tion reagent N-ter were used as negative controls. The concentration
was determined from the initial experiments optimizing the concentra-
tion for the minimum concentration of siRNA required to knock
down Bcl2 and Smad3 more than 80%. The level of Bcl2 and Smad3
expression was determined by immunoblot using a Bcl2 and Smad3
antibody, 72 hours after transfection. Three independent experiments
were conducted to determine specific silencing of the targeted Bcl2 and
Smad3 genes. Bcl2 and Smad3 siRNA sequences are available on re-
quest. Apoptosis assays were performed after treating the transfected
cells for 48 hours with carboplatin, 24 hours after transfection.
Stable Overexpression of Bcl2
A549 and HPL1A cells were stably transfected with Bcl2-pCDNA3
or pCDNA3 vector. Transfected cells were selected for 2 weeks in the
presence of G418, 600 μg/ml for A549, and 400 μg/ml for HPL1A
cells. Polyclonal population cells were used to isolate clones and the
expression of Bcl2 in each clone was verified by immunoblot analy-
sis using Bcl2 antibody. Clones that expressed a higher level of Bcl2
were selected for experiments and maintained in RPMI containing
10% FBS in the presence of 300 μg/ml for A549 and 200 μg/ml for
HPL1A cells.
Stable Overexpression of Smad3
The 300-day CSC-treated A549 cells were stably transfected with
Smad3-pCDNA3 or pCDNA3 vector. Transfected cells were selected
for 2 weeks in the presence of G418, 400 μg/ml for 300 days for A549,
and 200 μg/ml for 300 days for HPL1A cells. Polyclonal population
cells were used to isolate clones, and the expression of Smad3 in each
clone was verified by immunoblot analysis using Smad3 antibody.
Clones that expressed a higher level of Smad3 were selected for experi-
ments and maintained in RPMI containing 10% FBS in the presence
of 300 μg/ml for A549 and 150 μg/ml for HPL1A cells.
Smad3 and Bcl2 Expression in Public Database
We analyzed raw microarray data files from published NSCLC
cohort microarray databases to assess the expression of the Smad3
in clinical samples of NSCLC. We used 361 adenocarcinomas from
a recent multisite blinded validation study by the Director’s Chal-
lenge Consortium for the Molecular Classification of Lung Adeno-
carcinoma [28] that were initially surgically resected in Memorial
Sloan-Kettering (n = 104), University of Michigan (n = 178), and
H. Lee Moffitt Cancer Center (n = 79) (National Cancer Institute
Cancer Array database, experiment ID 1015945236141280,1; https://
caarraydb.nci.nih.gov/caarray). We excluded adenocarcinomas from the
Dana Farber Institute within the same report because of their reduced
total gene expression levels as well as samples that were excluded in their
original report. All NSCLC samples analyzed included only those that
passed the quality checks in the original published reports of the men-
tioned cohorts. In addition, each gene expression sample analyzed repre-
sents one unique patient. All raw data files were imported and analyzed
using the BRB-ArrayTools v.3.7.0 Beta Genes were normalized inde-
pendently by cohort. Common genes present in all gene chip platforms
(Affymetrix HG-U133A, HG-U133 plus 2.0, and U95A; Affymetrix,
Santa Clara, CA) were identified using NetAffx http://www.affymetrix.
com/analysis/index.affx. The expression of Smad3 was analyzed in the
aforementioned cohort. The z scores were calculated and plotted using
GraphPad Prism Software (GraphPad, La Jolla, CA).
Statistical Analysis
Descriptive statistics including mean values and SD were calculated
using Prism software (GraphPad). All data are representative of at least
three independent experiments and are expressed as the means ± SD
unless otherwise indicated. Analysis of variance was used to assess the
differences between experimental groups and survival curves, unless
otherwise indicated.
Results
Long-term CSC Treatment Imparts Carboplatin Resistance
In our previous study, we have shown that long-term CSC treatment
increases cell viability by decreasing apoptosis through down-regulation
of Smad3 [27]. To test whether long-term cigarette smoking contrib-
utes to the resistance to carboplatin-based chemotherapy in lung can-
cer, we analyzed the cytotoxic effects of carboplatin treatment in various
time points of CSC-treated A549 (lung adenocarcinoma) and HPL1A
(immortalized bronchial epithelial) cell lines using MTT cell viability
assay. The long-term CSC-treated cells (300 days) were much more
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resistant to carboplatin treatment compared with the corresponding
control (300-day DMSO-treated) cells. In A549, the half-maximal
inhibitory concentration (IC50) of carboplatin for 300-day CSC-treated
cells was 167.5 μM, whereas the corresponding control (300-day
DMSO-treated) cells had an IC50 of 72.3 μM (Figure 1A). We saw
the similar effect in HPL1A cells. The IC50 of 300-day CSC-treated
cells was 131.7 μM, whereas the IC50 of 300-day DMSO-treated cells
was 55.0 μM (Figure 1B). In addition, we observed that the IC50 of the
cell lines increased with the increasing time of treatment of CSC. Bim,
a proapoptotic factor, is a downstream target of Smad3. Since in our
previous study, we elucidated that Smad3 expression goes down in
long-term CSC treatment, we wanted to examine whether the expres-
sion levels of Bim are affected. To answer the question, we performed
immunoblot analyses with the cell lysates prepared from long-term
CSC-treated cells and control cells. There was no difference in the
expression of Bim in the long-term CSC-treated A549 and HPL1A
cells (Figure 1C). Resistance to the cytotoxic effects of carboplatin in
the long-term CSC-treated cell lines was evidenced by a plateau pattern
at lower doses of treatment. Taken together, these results may suggest
that long-term CSC treatment makes the cells resistant to carboplatin-
based chemotherapy.
CSC Treatment Induces Resistance to Carboplatin by
Abrogating Apoptosis
It is known that, in many cases, the cells become resistant to chemo-
therapeutic drugs due to less induction in apoptosis by drugs. To test
whether apoptosis is playing a role in CSC-induced resistance, we
conducted apoptosis studies by FACS analyses. The 300-day DMSO-
and CSC-treated cells were treated with fixed concentration of carbo-
platin for 48 hours and then analyzed for apoptosis induced by Annexin
V–PI staining. A representative image of the FACS analysis is shown in
Figure W1. Quantitating the results from four different experiments,
we observed that, in the control DMSO-treated cells, carboplatin
strongly induced cell death from 5% to 23% in A549 and from 3%
to 40% in HPL1A. However, in the long-term CSC-treated cells,
the carboplatin-induced apoptosis increased from 2% to 5% in A549
and 4% to 10% in HPL1A cells (Figure 2, A and C). Thus, the long-
term CSC treatment abrogated carboplatin-mediated apoptosis in both
cell lines. To confirm the induction of apoptosis by another method,
we performed immunoblot analyses of cleaved PARP, another hallmark
of apoptosis, in the lysates from cells treated with increasing concen-
tration of carboplatin for 48 hours. We observed a dose-dependent
increase in PARP cleavage in the DMSO-treated A549 and HPL1A
cells. CSC-treated cells did not show any PARP cleavage (Figure 2, B
and D). Carboplatin often cause cell cycle arrest in the G2/M phase.
An arrest of the cells in the G2/M phase is seen as inhibitory to the
cytotoxic processes of the drug. To test whether long-term CSC treat-
ment causes the cells to be arrested more in the G2/M phase in response
to carboplatin, we performed cell cycle analyses using FACS. Cells
were treated with carboplatin for 48 hours and the percentages of cells
having 2N DNA content were quantitated (as a measure of G2/M
phase). We observed that, in the long-term CSC-treated cells, the
carboplatin-induced arrest in the G2/M phase was higher than in the
corresponding control cells (Figure 2E). Taken together, these results
Figure 1. Long-term CSC treatment makes the cells resistant to carboplatin due to up-regulation of Bcl2. (A, B) 300-day CSC-treated cells
and 300-day DMSO-treated (control) A549 (A) and HPL1A (B) cells were treated with carboplatin for 72 hours, and cell viability was
assessed as measured by MTT activity. Data are represented as a percentage of MTT activity where untreated cells were taken to
be 100%. The IC50 and the corresponding SD were calculated from six individual experiments. (C) Bim expression 300-day CSC-treated
samples and controls in A549 (left) and HPL1A (right) cells by immunoblot analysis. β-Actin was used as a loading control.
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suggest that long-term CSC treatment abrogates carboplatin-induced
apoptosis by arresting cells in the G2/M phase of the cell cycle.
Bcl2 Is Important for the Inhibition of
Carboplatin-Induced Apoptosis
CSC contains thousands of compounds composed of five known
human carcinogens and many toxic agents. These may affect different
pathways ultimately leading to increased carboplatin resistance. To test
whether Smad3-mediated Bcl2 up-regulation is involved in CSC-
induced chemoresistance,we performed rescue experiments by knocking
down Bcl2 in long-term CSC-treated cells by siRNA. We trans-
fected Bcl2 siRNA and a control scrambled siRNA in the long-term
CSC-treated cells (both A549 and HPL1A). The next day, cells were
treated with carboplatin for 48 hours and checked for apoptosis by
FACS analysis. Immunoblot analyses were performed at the same
points to verify the knockdown of Bcl2 in the 300-day CSC-treated
cells (Figure 3, A and B, upper panels). In support of our hypothesis,
we observed that, after knocking down Bcl2 in the long-term CSC-
treated cells, there is a significant increase in the induction of apoptosis
in both cell lines when compared with scrambled siRNA-transfected
cells. These results suggest that Bcl2 is important for the long-term
CSC-treated cells to become resistant to carboplatin-mediated apop-
tosis. To confirm that Bcl2 is sufficient to make the cells resistant to
carboplatin, we overexpressed exogenous Bcl2 in the parental A549
and HPL1A cells where the expression of Bcl2 is low (Figure 3, C
and D, upper panels). To test whether overexpression of Bcl2 decreases
the sensitivity to carboplatin-mediated apoptosis, we treated the Bcl2-
overexpressing clones along with parental and vector control cells with
carboplatin for 48 hours. We observed that the Bcl2-overexpressing
clones were resistant to carboplatin-mediated apoptosis compared with
the parental and vector control cells (Figure 3, C and D, lower panels).
We then determined the IC50 of carboplatin in both the clones stably
overexpressing Bcl2 along with the control cells. Stable overexpres-
sion of Bcl2 in the parental A549 and HPL1A cells increased the
IC50 of carboplatin in both cell lines (Figure 3E ). The average IC50
of carboplatin for Bcl2-overexpressing clones was 100 μM for A549
and 125 μM for HPL1A, whereas the average for the parental and
vector control cells was 25 μM for A549 and 50 μM for HPL1A cells.
Figure 2. Long-term CSC treatment makes cells resistant to carboplatin through the abrogation of apoptosis. (A, C) Percentage of apoptotic
cells detected by Annexin V–PI staining on the 300-day CSC-treated and control for both A549 and HPL1A cells treated with carboplatin
70 μM for 72 hours analyzed by FACS analysis. Quantitation and statistical analysis were calculated from four individual experiments.
(B, D) Immunoblot analysis for checking the expression of cleaved caspase 3 (upper panels) and cleaved PARP (third panels) in 300-day
CSC-treated and control A549; HPL1A cells after being treated with increasing concentration of carboplatin at 35 and 70 μM for 48 hours.
β-Actin was used as a loading control. (E) Cell cycle analysis of 300-day CSC-treated cells and control cells (300-day DMSO-treated) after
treating with carboplatin for 48 hours. Figure shown is a representative of four different experiments.
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Figure 3. Bcl2 is involved in making cells resistant to carboplatin. (A) Immunoblot showing the Bcl2 expression in the 300-day CSC-treated
A549 and HPL1A cells transfected with siRNA (20 nM) directed against Bcl2 and scrambled control. β-Actin was used as a loading control.
Percentage of apoptotic cells detected by Annexin V–PI staining in the 300-day CSC-treated cells after no treatment (white) or after treatment
with 70 μM carboplatin (black) for 48 hours after transfection with siRNA against Bcl2 and scrambled control. Statistical analyses were
calculated based on four individual experiments. (B) Immunoblot showing the Bcl2 expression in the Bcl2-overexpressing clones in the
A549 and HPL1A cells. β-Actin was used as a loading control. (C) Fold induction of apoptosis by Annexin V–PI staining in parental, Bcl2-
overexpressing clones, and vector control after treatment of 70-μM carboplatin compared to no treatment of carboplatin in the
corresponding clones for 48 hours. Statistical analyses were calculated based on four individual experiments. (D) Parental A549, HPL1A,
Bcl2-overexpressing clones, and vector controls were treated with varying concentrations of carboplatin for 72 hours and assayed for
cell viability as measured by MTT activity. The IC50 was calculated as described in Materials and Methods. SDs were calculated based
on triplicate data points for each concentration. Statistical analyses were calculated based on three individual experiments.
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Taken together, these experiments suggest that Bcl2 is necessary and
sufficient for long-term CSC-treated cells to be resistant to carboplatin-
induced apoptosis.
ABT-737 Sensitizes the Long-term CSC-Treated Cells
to Carboplatin
Numerous examples of an enhanced apoptotic response when the
BH3 mimetics are combined with traditional therapies in various can-
cer models, such as melanoma, pancreatic, glioma, breast, multiple
myeloma, and B-cell malignant models, exist in the literature [29–
31]. We wanted to test whether the BH3 mimetic ABT-737 would
sensitize the cells to carboplatin in our in vitro model system through
the regulation of Bcl2. We treated 300-day CSC-treated cells and the
control cells with increasing concentrations of ABT-737 for 48 hours
and assayed for apoptosis. We observed that ABT-737 induced more
apoptosis in the 300-day CSC-treated cells compared with the control
cells in both A549 and HPL1A cell lines in a dose-dependent manner
(Figure 4A and B, upper panels). The sensitivity of ABT-737 depends
on the expression of another antiapoptotic Bcl2 family protein, Mcl1
[32]. To test whether increased levels of Mcl1 are contributing to the
increased sensitivity to ABT-737, we performed immunoblot analyses
using 300-day DMSO- and CSC-treated A549 and HPL1A cells. We
observed that the expression of Mcl1 does not change because of CSC
treatment (Figure 4, A and B, lower panels), suggesting that the in-
creased sensitivity of ABT-737 is not due to an increased expression
of Mcl1. To test whether ABT-737 can sensitize the 300-day CSC-
treated cells selectively to carboplatin-mediated apoptosis, we treated
300-day CSC-treated cells along with DMSO-treated cells with the
same concentration of carboplatin and increasing concentrations of
ABT-737 for 48 hours and assayed for apoptosis by FACS analyses.
We observed that the fold induction of apoptosis by ABT-737 on
top of carboplatin in both cell lines was higher in the 300-day CSC-
treated cells compared with the control cells (Figure 4C , left and right
panels). To test whether the ABT-737 could sensitize the 300-day
CSC-treated cells to carboplatin, we determined the IC50 of carbo-
platin with increasing concentrations of ABT-737. We observed that
ABT-737 decreased the IC50 of carboplatin in both cell lines in a
dose-dependent manner (Figure 4D). We also tested the reversibility
of the effect of long-term CSC treatment on carboplatin-induced apop-
tosis by withdrawing the CSC treatment and performing apoptosis
assays induced by carboplatin. We observed that there was no change
in the carboplatin-induced apoptosis when CSC treatment was with-
drawn for 21 days (Figure W2). Taken together, these results suggest
a potential for ABT-737 to be used in combination with carboplatin
to improve the therapeutic efficacy in smokers.
Smad3 Induces Sensitivity of Carboplatin in Long-term
CSC-Treated Cells by Downregulating Bcl2
In one of our recent studies, we have shown that the expression of
Smad3 decreases in the long-term CSC-treated cells, which is associated
with the increased expression of Bcl2. To test whether Smad3 can alter
the sensitivity of long-term CSC-treated cells, we stably expressed
Smad3 in the 300-day CSC-treated A549 and HPL1A cells and then
verified the expression of Smad3 and Bcl2 in clones by immunoblot
analyses (Figure 5A). We observed that Bcl2 expression is reduced
in the Smad3-overexpressing clones (Figure 5A). To test whether re-
expression of Smad3 can resensitize the cells to carboplatin-mediated
apoptosis, we treated the Smad3-overexpressing clones, vector control,
and the 300-day CSC-treated cells (both A549 and HPL1A) with
carboplatin and assayed for apoptosis. We observed that Smad3-
overexpressing clones from 300 days CSC-treated cells showed a much
higher fold induction in apoptosis than the 300-day CSC-treated
parental and the vector control cells (Figure 5B). We extended the
results further and tested whether the Smad3 overexpression can
actually sensitize (decrease the IC50) the 300-day CSC-treated cells to
carboplatin. We observed that the IC50 of carboplatin was less in the
Smad3-overexpressing clones compared with the parental (300-day
CSC-treated) and the vector controls in both A549 and HPL1A
cell lines (Figure 5C ). The average IC50 of carboplatin for Smad3-
overexpressing clones was 85 μM for A549 and 100 μM for HPL1A,
whereas the average for the parental and vector controls was 130 μM
for A549 and 150 μM for HPL1A cell lines. These results suggest that
Smad3 regulates the expression of Bcl2 and, in turn, controls the
sensitivity of the 300-day CSC-treated cells to carboplatin.
Loss of Smad3 Expression in CSC-Treated Cells Induces
Resistance to Carboplatin by Upregulating Bcl2
Smad3 has many downstream targets, and overexpression of Smad3
can regulate other pathways that may contribute to the increased
sensitivity other than the down-regulation of Bcl2. We hypothesize
that the sensitivity to carboplatin-mediated apoptosis in the Smad3-
overexpressing clones is exclusively due to down-regulation of Bcl2
and not some off-target effects. To test this hypothesis, we used Smad3
siRNA to suppress Smad3 expression in the Bcl2-overexpressing
clones in both A549 (clone 7; Figure 3C) and HPL1A (clone 13; Fig-
ure 3D) cell lines. Immunoblot analyses performed in parallel ex-
periments demonstrated the successful knockdown of Smad3 in the
Bcl2-overexpressing clones (Figure 6, A and B, upper panels). The loss
of Smad3 in the Bcl2-overexpressing clones did not change apoptosis
by carboplatin treatment in both cell lines (Figure 6, A and B, lower
panels). Taken together, these results demonstrate that loss of Smad3
expression induces resistance to carboplatin in 300-day CSC-treated
cells specifically through Bcl2.
Correlation between Smad3 and Bcl2 Expression in
Lung Tumors
In our in vitro model system, we observed that loss of Smad3
expression in CSC-treated cells increases the expression of Bcl2. To ver-
ify whether this inverse correlation between the expression of Smad3
and Bcl2 is present in lung tumors, we looked into the public database
[28] to investigate the correlation between Smad3 and Bcl2 mRNA
expressions. We found that patients with lung cancer with higher levels
of Smad3 have lower levels of Bcl2 and patients with lower levels of
Smad3 have relatively higher levels of Bcl2 mRNA expressions (Fig-
ure 7). These results are statistically significant. These data suggest
that an inverse correlation exists between the expressions of Smad3
and Bcl2 in lung tumors.
Discussion
In this study, we have used an in vitromodel to mimic long-term smok-
ing in human lung cancer. We have treated a lung adenocarcinoma cell
line (A549) and an immortalized bronchial epithelial cell line (HPL1A)
with CSC for various time points of treatment. We have demonstrated
that long-term CSC treatment makes the cells resistant to carboplatin
and that Smad3 is involved inmaking the cells resistant to chemotherapy.
To our knowledge, this is the first time we show that Smad3 is respon-
sible for creating resistance to chemotherapy in human cancer and that
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Figure 4. ABT-737 resensitizes the long-term CSC-treated cells to carboplatin. (A) The 300-day CSC-treated (300-day DMSO-treated cells
as a control) A549 and HPL1A cells were treated with increasing concentrations of ABT-737 for 48 hours, and the percentage of cells
undergoing apoptosis was detected by Annexin V–PI staining. Statistical analyses were calculated based on four individual experiments.
(B) Cell lysates from 300-day CSC treatment and controls were analyzed by immunoblot analysis with proapoptotic anti-Mcl1 antibody.
An equal amount of protein loading was verified by immunoblot analysis with anti–β-actin antibody. (C) Fold induction of apoptosis in
300-day CSC-treated A549 and HPL1A cells along with control cells were treated with or without 70 μM carboplatin and increasing
concentration of ABT-737 (0-1.5 μM) assayed by Annexin V–PI staining. Fold induction was calculated from the ratio of percentage
of cells undergoing apoptosis undergoing treatment with respect to the apoptosis in the untreated samples. Error bars are represen-
tative of four independent experiments. (D) The 300-day CSC-treated cells treated with carboplatin (0-250 μM) in the presence of increasing
concentrations of ABT-737 0, 0.5, 1.0, or 1.5 μM for A549 and 0, 2.5, 5, or 7.5 μM for HPL1A cells for 72 hours were assessed for cell
cytotoxicity as measured by MTT activity. Data are presented as a percentage of MTT activity where untreated cells were taken to be
100%. Error bars are representative of four independently treated samples.
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there is an inverse correlation between the expression of Smad3 and Bcl2
in lung cancer.
Stabilization and activation of wild-type p53 are critical for cisplatin-
mediated apoptosis. Therefore, the tumor cells devoid of the wild-type
p53 function fail to activate the cell death program. Thus, the cells
become tolerant to DNA damage, which is a feature characteristic of
resistance caused by disruption in signal transduction pathways [33–
36]. However, both data from the NCI panel of cell lines and clini-
cal cases demonstrated that the sensitivity or resistance to cisplatin is
irrespective of p53 gene status [36,37]. Similar to these observations,
we also observed that the resistance to cisplatin is irrespective of the
status of p53 (Figure 1). In HPL1A cells, p53 is inactivated due to
immortalization by SV-40 large T antigen, whereas the other cell line
A549 has wild-type active p53. Despite this difference in p53 status,
long-term CSC treatment makes the cells resistant to carboplatin treat-
ment. Another genetic factor, which might contribute to the sensitivity
to carboplatin, is K-ras mutation, which can activate various pathways
namely PI3K/Akt and mitogen-activated protein kinase. However,
we have observed carboplatin resistance in both the A549 and the
HPL1A cells. These studies indicate that the sensitivity to carboplatin
is irrespective of the K-ras mutation status.
The relationship between cell cycle arrest and cytotoxicity is com-
plex and not fully deciphered. According to the current dogma, cell
cycle arrest is seen as inhibitory to the cytotoxic process. This conclu-
sion is derived primarily from the demonstration that pharmacological
abrogation of the G2/M checkpoint increases cellular sensitivity to cis-
platin [38,39]. Cells undergo apoptosis only when repair is incomplete
by excessive DNA damage. We have found that the long-term CSC
treatment makes the cells arrest in the G2/M phase of cell cycle and
as a result exhibited decreased apoptosis (Figure 2, A, C , and E). This
could be due to the up-regulation of Bcl2. Recently, it has been shown
that overexpression of Bcl2 is responsible for the arrest of the cells in
the G2/M phase through the induction of cyclin-dependent kinase
inhibitors, namely, p27, p21, and p16 [40]. We have shown that
the up-regulation of Bcl2 that is observed in smokers with NSCLC
not only is an epiphenomenon but also is mechanistically involved
in the development of carboplatin resistance.
It has been shown that ABT-737, a BH3 mimetic, binds to anti-
apoptotic Bcl2 family proteins and disrupts the sequestering and
neutralizing proapoptotic proteins, namely, Bim and Bid. The drug
has shown efficacy on administration as both a monotherapy and in
combination with cytotoxic therapies in preclinical studies of other
cancer types. Even in our long-term CSC-treated cell lines ABT-737
induced apoptosis, the putative reason for little induction in apopto-
sis may be due to the relatively high expression of Mcl1 in the cell
lines (Figure 4, A and B). The sensitivity of ABT-737 to long-term
Figure 5. Smad3 expression mediates, in part, the cytotoxic effects of carboplatin. (A) Immunoblot showing the protein expression of
Smad3 and Bcl2 in Smad3-overexpressing clones and vector control in the 300-day CSC-treated A549 and HPL1A cells. An equal amount
of protein loading was verified by immunoblot analysis with anti–β-actin antibody. (B) Fold induction of apoptosis in the 300-day CSC-
treated cells, vector controls and Smad3-overexpressing clones after treatment of 70-μM carboplatin for 48 hours. Fold induction was
calculated from the ratio between percentage of cells undergoing apoptosis with treatment and without treatment of carboplatin in the
corresponding cells. Error bars were calculated from four individual experiments. (C) The 300-day CSC-treated A549 and HPL1A, Smad3-
overexpressing clones, and vector controls were treated with varying concentration of carboplatin for 72 hours and assayed for cell
viability as measured by MTT activity. Data are presented as a percentage of MTT activity where untreated cells were taken to be
100%. Error bars are representative of four independently treated samples.
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CSC-treated cells is not due to the decreased expression of antiapoptotic
Mcl1 as shown previously in some model systems. The differential
sensitivity is due to the higher expression of Bcl2 from long-term CSC
treatment as shown in previous studies [41,42]. The other niche for
these drugs is in combination therapy, where the Bcl2 antagonist serves
to inhibit Bcl2-mediated resistance, thus enabling the conventional
chemotherapy to kill cells. Here, we show that ABT-737 can improve
the efficacy of carboplatin in lung cell lines.
After smoking cessation, the cumulative death risk from lung cancer
decreases. Peto et al. [43] showed that the earlier cigarette smoking is
stopped, the greater the decline in lung cancer mortality. There is a
pressing need to clarify the role of smoking cessation in resistance to
chemotherapy observed in patients with lung cancer who smoke. To
mimic the conditions of smoking cessation, we withdrew cells from
the long-term (300-day) CSC treatment for 21 days and tested for
the effect of carboplatin treatment. We observed that withdrawal of
Figure 7. Smad3 and Bcl2 expressions are inversely correlated in NSCLC. (A) Box plot of Bcl2 expression as a function of Smad3 expres-
sion status in patient tumor samples from public database. P values calculated by Student’s t test. (B) Model of the long-term smoking-
induced carboplatin resistance. In normal lung cells, carboplatin induces caspase-dependent apoptosis. Long-term CSC treatment results
in reduced expression of Smad3, which results in the up-regulation of antiapoptotic Bcl2 that creates resistance to carboplatin by blocking
caspase-dependent apoptosis. This long-term CSC-treated cell can be resensitized with BH3-mimetic, ABT-737.
Figure 6. Smad3makes the cells resistant to carboplatin-mediated apoptosis specifically through the Bcl2 pathway. (A) Expression of Smad3
and Bcl2 in the Bcl2-overexpressing clones of A549 and HPL1A cells after transfection of Smad3 siRNA (20 nM) and scrambled control by
immunoblot analysis. β-Actin was used as a loading control. (B) Percentage of cells undergoing apoptosis in the Bcl2-overexpressing clones
in A549 and HPL1A cells after being transfected with Smad3 siRNA and scrambled control and treated with carboplatin 50 μM for 48 hours.
Error bars are calculated from four individual experiments.
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CSC does not have any effect on the IC50 of carboplatin and also
carboplatin-mediated apoptosis. From this, we can infer that 1) smok-
ing cessation has no effect on resistance to carboplatin-based chemo-
therapy observed in smokers and that 2) the synergistic effect of
ABT-737 and carboplatin is limited to patients with NSCLC who
are smokers. It is plausible that withdrawing CSC treatment for 21 days
may not exactly recapitulate the effect of smoking cessation in smokers.
In our previous study, we showed that long-term CSC treatment
downregulates Smad3 expression, which results in a decrease in apop-
tosis [27]. Our current results show that loss of Smad3 expression in
CSC-treated cells upregulates the expression of Bcl2 that in turn de-
creases apoptosis (Figure 5, A and B). Further, the regulation of Bcl2
expression by Smad3 has a causal effect in decreasing the IC50 of carbo-
platin by decreasing the carboplatin-induced apoptosis (Figure 5C ).
This is also in agreement with in vivo studies that have shown that
blocking TGF-β signaling can result in resistance to DNA-damaging
agents including cisplatin [44,45]. Bim, a proapoptotic factor, is known
to be induced by Smad3 in B lymphocytes [46]. In our model, we do
not see any change in Bim levels (Figure 1C) even when Smad3 expres-
sion is reduced due to CSC treatment. It is quite possible that the reg-
ulation of Bim expression by Smad3 is context dependent. We did not
observe any change in the expression of other members of the Bcl2
family in response to CSC in our previous study [27]. These results
demonstrate that Smad3 induces carboplatin resistance by regulating
the expression of Bcl2. The in vitro results of the inverse relationship
between the expression of Smad3 and Bcl2 also holds true in patients
with lung cancer at the mRNA levels (Figure 7A). To our knowledge,
this is the first study to show the inverse correlation between the expres-
sions of these two genes in lung cancer. It is worth exploring whether
reduced expression of Smad3 and high expression of Bcl2 can serve
as a prognostic or predictive biomarker for carboplatin-based chemo-
therapy. On the basis of the observations, we propose a model that
long-term CSC treatment induces an intrinsic resistance to carboplatin
by upregulating the antiapoptotic protein Bcl2 (Figure 7B). The up-
regulation of Bcl2 is mediated by the reduced expression of Smad3
in CSC-treated cells. This intrinsic resistance to carboplatin induced
by long-term smoking can be overcome by treating with BH3 mi-
metics, ABT-737. In addition, our previous report would also suggest
that HDAC inhibitors might also resensitize the long-term CSC-
treated cells to carboplatin by restoring the expression of Smad3 [27].
Contemporary first-line chemotherapy in advanced stage lung
cancer traditionally involves platinum-based drugs. In lung cancer,
resistance to cancer drugs presents a major problem, limiting the
effectiveness of chemotherapy. There is a pressing need to identify pre-
dictive biomarkers for stratifying and subgrouping patients with lung
cancer for platinum-based therapy. Our results serve as an example
of the utility of in vitro model for defining the subset of patients with
favorable outcomes with particular treatment strategy. Our data suggest
that patients with lung cancer who are smokers and have low expres-
sion of Smad3 would be resistant to platinum-based chemotherapy
and the therapeutic efficacy can be improved by adding Bcl2 inhibi-
tor ABT-737. After appropriate preclinical validation, these results
may lead to a definitive subset of patients who would benefit from
platinum-based chemotherapy or suggest how the response of the
resistant patients could be improved.
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Figure W1. Long-term CSC treatment induces resistance to carboplatin-induced apoptosis: Representative figure of induction of apop-
tosis in the long-term CSC-treated cells and control cells treated with 70 μM carboplatin for 48 hours in A549 cells (upper panel) and
HPL1A cells (lower panel). After 48 hours, cells were trypsinized, and FACS analysis was performed as described in Materials and
Methods. The figures were generated using FlowJo software. We can see in the control cells that carboplatin induces apoptosis in both
A549 (upper second panel from left) and HPL1A cells (lower second panel). However, long-term CSC treatment abrogates carboplatin-
induced apoptosis in both A549 (upper rightmost panel) and HPL1A cells (lower rightmost panel).
Figure W2. Withdrawal of CSC treatment does not resensitize the cells to carboplatin: (A) To mimic the effect of smoking cessation,
CSC treatment was withdrawn after treating cells for 300 days for varying periods, namely, 7, 14, and 21 days. For determination of
IC50, the various time points of withdrawal cells were treated with varying concentration of carboplatin for 72 hours and assayed for
cell viability as measured by MTT activity. SDs were calculated based on triplicate data points for each concentration. DW indicates
days of withdrawal. (B) For determination of carboplatin-mediated apoptosis, 300-day CSC-treated cells and various time points of CSC
withdrawal cells (along with corresponding controls) were treated with 70 μM carboplatin and cell lysates were prepared. Immunoblot
analysis showing the expression of cleaved caspase 3 and cleaved PARP with and without carboplatin treatment when A549 cells were
withdrawn from CSC treatment for 7, 14, and 21 days after being treated with CSC and DMSO for 300 days. The withdrawal of CSC
treatment does not resensitize the cells to carboplatin or carboplatin-induced apoptosis.
